Thelansis

Hypophosphatasia Market Outlook Thelansis’s “Hypophosphatasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypophosphatasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights...

Hypophosphatasia Market Outlook Thelansis’s “Hypophosphatasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypophosphatasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Hypophosphatasia Overview Hypophosphatasia (HPP) is the inborn error of metabolism caused by a loss-of-function mutation(s) in the gene that encodes the tissue-nonspecific isozyme of alkaline phosphatase (TNAP). The disease has been classified according to patient age when the first signs and symptoms manifest, i.e., perinatal, infantile, childhood, adult HPP. Other types include odonto HPP and perinatal benign. Babies with the perinatal/immature forms of...

  Hypophosphatasia (HPP) arises from a genetic anomaly affecting the gene responsible for encoding tissue-nonspecific isozyme of alkaline phosphatase (TNAP), resulting in a loss-of-function mutation(s). The disease presents across various stages of life, classified into perinatal, infantile, childhood, and adult HPP, along with odonto HPP and perinatal benign forms. Perinatal/immature HPP often proves fatal, characterized by severe rickets, respiratory insufficiency, hypercalcemia, and sometimes vitamin B6-responsive seizures in affected infants. The principal biochemical deficiency in HPP involves reduced TNAP activity, leading to elevated levels of substrates, particularly inorganic pyrophosphate (PPi), a potent calcification inhibitor. The clinical severity varies widely. Strensiq (asfotase alfa), an FDA-approved medication, addresses hypophosphatasia (HPP) in children. Initially sanctioned in 2015, it targets childhood-onset, juvenile-onset, and perinatal HPP. Strensiq, a rec...

  Hypophosphatasia – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032